BioTime's CEO Michael West to Present Preclinical Data on OTX-CP03 and OTX-CP07 for the Treatment of Osteoarthritis at STEM 2011 in Gurgaon, India

(BUSINESS WIRE)--BioTime, Inc. (NYSE Amex:BTX) and its subsidiary OrthoCyte Corporation announced today that BioTime’s CEO Dr. Michael West will present at STEM 2011 in Gurgaon, India on January 31, 2011. The conference is the 7th Annual Conference on Biotechnology sponsored by the Society for Regenerative Medicine and Tissue Engineering. Dr. West’s presentation titled, “Progress in the commercialization of human embryonic stem cell technology” will disclose animal preclinical data on the scalability, safety, and efficacy of OTX-CP03 and OTX-CP07 for the treatment of osteoarthritis. OTX-CP03 and OTX-CP07 are purified and scalable embryonic progenitor cells for human cartilage derived from human embryonic stem cells using the Company’s proprietary ACTCellerate™ platform. Dr. West’s presentation will be available on BioTime’s website (www.biotimeinc.com) today to coincide with the beginning of the 29th Annual J.P. Morgan Healthcare Conference in San Francisco, being held January 10-13, 2011, during which BioTime will be conducting numerous investor meetings.